EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ASCP explores the cancer biomarker testing navigator as a novel role to improve laboratory operations and workflows: A special report from the ASCP Biomarker Testing Navigator Project Team

Lynnette Pineault, Karla Valencia, Jennifer Buhay, Alexandra Brown, Suzanne Ziemnik, Melissa Kelly, James Morgante, Ananya Datta Mitra, Lindsay Yanamura, Marie Gilliland, Amy Ferea, Joseph Kim iD

American Journal of Clinical Pathology · 03.06.2025 · 163 (6) · 926-935

DOI: 10.1093/ajcp/aqaf028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 07.05.2025. Verfasst von Lynnette Pineault und 11 weiteren Autor:innen. Beteiligte Einrichtung: HealthPartners, Bloomington, MN, United States. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Neoplasms, Pathology, Clinical, Laboratories, Clinical. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Cancer biomarker testing is a critical element in precision oncology, guiding treatment decisions and improving patient outcomes. However, the complexity and variability of biomarker testing processes present significant challenges for cancer centers, often leading to delays and inefficiencies that can compromise care quality. The American Society for Clinical Pathology explored the concept of a novel laboratory professional role: the cancer biomarker testing navigator (BTN).

Methods

This study explored the feasibility and impact of the BTN role on laboratory operations and workflows through a 3-phase project consisting of a quantitative needs assessment, qualitative focus group discussions, and a short-term feasibility pilot conducted at 2 cancer centers.

Results

The needs assessment revealed that many laboratories lack dedicated staff for coordinating biomarker testing, leading to operational inefficiencies. The roundtable discussions highlighted common challenges in biomarker testing and identified potential benefits of the BTN role, such as improved communication, better tracking of send-out tests, and enhanced task efficiency. The feasibility pilot demonstrated that BTNs could coordinate multigene next-generation sequencing panels and expedite key steps to ensure optimal preanalytical processes, reduce delays in testing, and smooth operations. The BTN role represents a feasible and beneficial addition to pathology laboratories that addresses key operational challenges in cancer biomarker testing and offers a promising solution to streamline laboratory operations, improve multidisciplinary communication, and enhance patient care coordination.

Conclusions

Further exploration is warranted to refine the BTN role and assess its long-term sustainability in and impact on diverse laboratory settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorNeoplasmsPathology, ClinicalLaboratories, ClinicalHumansWorkflowPilot Projects

Stichwörter der Autor:innen

ASCPbiomarker testing navigatorcancer biomarker testingfeasibility pilotqualitative focus groupsquantitative needs assessment

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • HealthPartners, Bloomington, MN, United States.
  • The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • American Society for Clinical Pathology, Chicago, IL, United States.
  • Department of Pathology, University of California Davis Health, Sacramento, CA, United States.
  • Spartanburg Regional Healthcare System, Spartanburg, SC, United States.
  • Q Synthesis LLC, Newtown, PA, United States.

ORCID-Profile: Joseph Kim

Förderung

  • AstraZeneca

Zitieren

APA

Pineault, L., Valencia, K., Buhay, J., Brown, A., Ziemnik, S., Kelly, M., Morgante, J., Datta Mitra, A., Yanamura, L., Gilliland, M., Ferea, A., & Kim, J. (2025). ASCP explores the cancer biomarker testing navigator as a novel role to improve laboratory operations and workflows: A special report from the ASCP Biomarker Testing Navigator Project Team. American Journal of Clinical Pathology, 163(6), 926-935. https://doi.org/10.1093/ajcp/aqaf028

Vancouver

Pineault L, Valencia K, Buhay J, Brown A, Ziemnik S, Kelly M, et al. ASCP explores the cancer biomarker testing navigator as a novel role to improve laboratory operations and workflows: A special report from the ASCP Biomarker Testing Navigator Project Team. American Journal of Clinical Pathology. 2025;163(6):926-935. doi:10.1093/ajcp/aqaf028

BibTeX
@article{Pineault2025,
  author = {Pineault, Lynnette and Valencia, Karla and Buhay, Jennifer and Brown, Alexandra and Ziemnik, Suzanne and Kelly, Melissa and Morgante, James and Datta Mitra, Ananya and Yanamura, Lindsay and Gilliland, Marie and Ferea, Amy and Kim, Joseph},
  title = {ASCP explores the cancer biomarker testing navigator as a novel role to improve laboratory operations and workflows: A special report from the ASCP Biomarker Testing Navigator Project Team},
  journal = {American Journal of Clinical Pathology},
  year = {2025},
  volume = {163},
  number = {6},
  pages = {926--935},
  doi = {10.1093/ajcp/aqaf028}
}
Kostenlos starten →